← back to search

David J. Inwards

Mayo Clinic in Arizona · US
Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, and Hematopoietic Stem Cell Transplantation.
h-index
69
citations
15,401
works
443
NIH funding
primary concept
email

Recent publications

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Blood Advances 2023cited by 15position: middledoi
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant
JAMA Oncology 2021cited by 79position: middledoi
Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis
American Journal of Hematology 2021cited by 36position: middledoi
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
Bone Marrow Transplantation 2021cited by 35position: middledoi
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant
JAMA Oncology 2020cited by 56position: middledoi
Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation
Cancer 2020cited by 24position: middledoi
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Journal of Clinical Oncology 2019cited by 97position: middledoi
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation 2019cited by 76position: middledoi
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation
JAMA Oncology 2019cited by 56position: middledoi
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis
Journal of Hematology & Oncology 2019cited by 37position: middledoi
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Journal of Clinical Oncology 2018cited by 138position: middledoi
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure
Cancer 2018cited by 74position: middledoi
History of autoimmune conditions and lymphoma prognosis
Blood Cancer Journal 2018cited by 38position: middledoi
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
Biology of Blood and Marrow Transplantation 2017cited by 139position: middledoi
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
American Journal of Hematology 2016cited by 225position: middledoi
Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation
British Journal of Haematology 2016cited by 132position: middledoi
A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma
Bone Marrow Transplantation 2015cited by 59position: middledoi
The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen
Biology of Blood and Marrow Transplantation 2015cited by 53position: middledoi
Impact of Pretransplantation 18F-fluorodeoxy Glucose–Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation 2015cited by 39position: middledoi
Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology 2014cited by 174position: middledoi
Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation 2014cited by 147position: middledoi
Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
Journal of Clinical Oncology 2014cited by 85position: middledoi
Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma
Biology of Blood and Marrow Transplantation 2014cited by 42position: middledoi
Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
Biology of Blood and Marrow Transplantation 2013cited by 100position: middledoi
Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma
Biology of Blood and Marrow Transplantation 2013cited by 92position: middledoi
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Blood 2012cited by 137position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Hillard M. Lazarus · Case Western Reserve University4 papers (2012–2020)James R. Cerhan · Mayo Clinic3 papers (2014–2018)Brian K. Link · University of Hassan II Casablanca3 papers (2014–2018)Robert Peter Gale · Chongqing Cancer Hospital3 papers (2012–2013)Rammurti T. Kamble · Webster University3 papers (2013–2020)John Gibson · Clinical Trial Investigators3 papers (2012–2013)Kwang Woo Ahn · Medical College of Wisconsin3 papers (2013–2020)Mitchell S. Cairo · New York Medical College3 papers (2012–2013)Thomas E. Witzig · Toyota Motor Corporation (Switzerland)3 papers (2014–2018)Mehdi Hamadani · Medical College of Wisconsin3 papers (2013–2020)Edmund K. Waller · Emory University3 papers (2012–2013)Carrie A. Thompson · Université Claude Bernard Lyon 13 papers (2014–2018)Thomas M. Habermann · Université Claude Bernard Lyon 13 papers (2014–2018)Parameswaran Hari · Medical College of Wisconsin3 papers (2012–2013)Harry C. Schouten · Medical College of Wisconsin3 papers (2012–2013)Jeanette Carreras · Medical College of Wisconsin3 papers (2012–2013)Matthew J. Maurer · Toyota Motor Corporation (Switzerland)3 papers (2014–2018)Grzegorz S. Nowakowski · Mayo Clinic3 papers (2014–2018)David A. Rizzieri · Novant Health3 papers (2013–2020)Timothy S. Fenske · Medical College of Wisconsin3 papers (2012–2013)